By Erin Marie Daly (June 1, 2007, 12:00 AM EDT) -- On the heels of warnings from federal regulators over the safety of its diabetes drug Avandia, GlaxoSmithKline is facing what may be the first of many product liability lawsuits over claims that it failed to disclose that the popular drug may significantly boost the risk of heart attack and heart-related death.
The proposed class action, filed Thursday in the U.S. District Court for the District of Puerto Rico, was brought by Celenio Cruz-Santana on behalf of himself and all similarly situated patients who took Avandia or related drugs Avandamet and Avandaryl, which are used to treat type 2 diabetes.
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!